These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11367103)

  • 21. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Top stories of 2008. Antiretroviral rollout--successes and challenges.
    Friedland GH
    AIDS Clin Care; 2009 Jan; 21(1):5. PubMed ID: 19219959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiation of antiretroviral therapy: implications of recent findings.
    Saag MS
    Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient adherence, not viral load now most important in HIV therapy.
    Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
    [No Abstract]   [Full Text] [Related]  

  • 26. The case of the undetectable viral load.
    Jenny-Avital ER
    AIDS Clin Care; 1999 Mar; 11(3):20-1. PubMed ID: 11366207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.
    Cassol E; Page T; Mosam A; Friedland G; Jack C; Lalloo U; Kopetka J; Patterson B; Esterhuizen T; Coovadia HM
    J Infect Dis; 2005 Feb; 191(3):324-32. PubMed ID: 15633090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).
    Pujari S; Patel A; Joshi SR; Gangakhedkar R; Kumarasamy N; Gupta SB;
    J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643
    [No Abstract]   [Full Text] [Related]  

  • 34. A kinder, gentler approach to treatment. Interview by Paul Simmons.
    Mauss S
    Res Initiat Treat Action; 1998 Aug; 4(5):3-5. PubMed ID: 11365708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral rounds. Should we mess with success?
    J Watch AIDS Clin Care; 2009 Aug; 21(8):63-5. PubMed ID: 19795534
    [No Abstract]   [Full Text] [Related]  

  • 36. Once-daily antiretroviral therapy among treatment-experienced Muslim patients fasting for the month of Ramadan.
    Yakasai AM; Muhammad H; Babashani M; Jumare J; Abdulmumini M; Habib AG
    Trop Doct; 2011 Oct; 41(4):233-5. PubMed ID: 21914677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One size does not fit all.
    Soloway B; Fichtenbaum CJ
    AIDS Clin Care; 2001 Oct; 13(10):92-3. PubMed ID: 11590922
    [No Abstract]   [Full Text] [Related]  

  • 38. How do you handle those borderline cases?
    AIDS Alert; 1998 May; 13(5):55-8. PubMed ID: 11365413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral therapy: an update.
    Reddy P; Ross J
    Conn Med; 1998 Jan; 62(1):25-8. PubMed ID: 9509709
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antiretroviral treatment: when to start and with what?].
    Soriano V; Jiménez-Nácher VS
    Med Clin (Barc); 1998 Jul; 111(4):137-41. PubMed ID: 9717146
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.